CL2023003187A1 - Regímenes de dosificación de conjugados peptídicos de inhibidores de la topoisomerasa i. - Google Patents

Regímenes de dosificación de conjugados peptídicos de inhibidores de la topoisomerasa i.

Info

Publication number
CL2023003187A1
CL2023003187A1 CL2023003187A CL2023003187A CL2023003187A1 CL 2023003187 A1 CL2023003187 A1 CL 2023003187A1 CL 2023003187 A CL2023003187 A CL 2023003187A CL 2023003187 A CL2023003187 A CL 2023003187A CL 2023003187 A1 CL2023003187 A1 CL 2023003187A1
Authority
CL
Chile
Prior art keywords
topoisomerase
inhibitors
peptide conjugates
dosing regimens
peptide
Prior art date
Application number
CL2023003187A
Other languages
English (en)
Spanish (es)
Inventor
Paralkar Vishwas
P Decillis Arthur
Original Assignee
Cybrexa 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 2 Inc filed Critical Cybrexa 2 Inc
Publication of CL2023003187A1 publication Critical patent/CL2023003187A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2023003187A 2021-04-29 2023-10-25 Regímenes de dosificación de conjugados peptídicos de inhibidores de la topoisomerasa i. CL2023003187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163181640P 2021-04-29 2021-04-29

Publications (1)

Publication Number Publication Date
CL2023003187A1 true CL2023003187A1 (es) 2024-05-03

Family

ID=81749580

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003187A CL2023003187A1 (es) 2021-04-29 2023-10-25 Regímenes de dosificación de conjugados peptídicos de inhibidores de la topoisomerasa i.

Country Status (12)

Country Link
US (1) US20240226308A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329817A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516825A (cg-RX-API-DMAC7.html)
KR (1) KR20240019097A (cg-RX-API-DMAC7.html)
CN (1) CN117897175A (cg-RX-API-DMAC7.html)
AU (1) AU2022267389A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218253A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003187A1 (cg-RX-API-DMAC7.html)
IL (1) IL308052A (cg-RX-API-DMAC7.html)
MX (1) MX2023012779A (cg-RX-API-DMAC7.html)
TW (1) TW202308696A (cg-RX-API-DMAC7.html)
WO (1) WO2022232808A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
CA3032186C (en) 2010-07-13 2022-04-26 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
SG10201913073YA (en) * 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20210106648A1 (en) * 2019-10-11 2021-04-15 TOBEBIO Novel Drug Laboratory Co., Ltd. Synergistic combination of chemotherapy and peptide for treating cancer

Also Published As

Publication number Publication date
KR20240019097A (ko) 2024-02-14
CA3218253A1 (en) 2022-11-03
IL308052A (en) 2023-12-01
AU2022267389A9 (en) 2023-11-16
AU2022267389A1 (en) 2023-11-09
CN117897175A (zh) 2024-04-16
EP4329817A1 (en) 2024-03-06
US20240226308A1 (en) 2024-07-11
MX2023012779A (es) 2024-01-16
WO2022232808A1 (en) 2022-11-03
JP2024516825A (ja) 2024-04-17
TW202308696A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
CO2021008224A2 (es) Inhibidores de kif18a
BR112022000337A2 (pt) Conjugados de peptídeos de citotoxinas como terapêuticos
ECSP22029777A (es) Heterociclos bic?clicos como inhibidores de fgfr
CO2022019316A2 (es) Inhibidores alostéricos de egfr y métodos de uso de estos
MX2022001181A (es) Inhibidores de kif18a.
BR112023000047A2 (pt) Compostos de ureia tricíclicos como inibidores da v617f da jak2
MX2022001302A (es) Inhibidores de kif18a.
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
CO6710897A2 (es) Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
MX381235B (es) Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer.
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
MX2023012779A (es) Regimenes de dosificacion de conjugados de peptido de inhibidores de topoisomerasa i.
MX2022001133A (es) Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
MX2024015493A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1
UY39779A (es) Compuestos macrocíclicos para tratar enfermedades
CL2024001486A1 (es) Conjugados peptidicos de inhibidores peptidicos de tubulina como terapeuticos.
BR112022000297A2 (pt) Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
CL2023002632A1 (es) Derivados de 3h,4h-tieno [2,3-d]pirimidin-4-ona como inhibidores de trpa1
CO2025018750A2 (es) Inhibidores de wrn
MX2024012368A (es) Terapia combinada para el tratamiento del cancer
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
MX2021009142A (es) Inhibidores topicos de fosfoinositol 3-cinasas.